title: Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis.
authors.forename: J Y
authors.initials: JY
authors.lastname: Reginster
authors.forename: J E
authors.initials: JE
authors.lastname: Compston
authors.forename: E A
authors.initials: EA
authors.lastname: Jones
authors.forename: J M
authors.initials: JM
authors.lastname: Kaufman
authors.forename: M
authors.initials: M
authors.lastname: Audran
authors.forename: G
authors.initials: G
authors.lastname: Bouvenot
authors.forename: L
authors.initials: L
authors.lastname: Frati
authors.forename: G
authors.initials: G
authors.lastname: Mazzuoli
authors.forename: C
authors.initials: C
authors.lastname: Gennari
authors.forename: E M
authors.initials: EM
authors.lastname: Lemmel
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000502:physiology; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D017277:Drug Approval; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control